DR a Shamani INC
DR a Shamani INC was paid $396K by Medicaid between Jan 2018 and Nov 2024, across 30 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 18% of everything it billed.
SAN DIEGO, CA 92120
Next to other Family Medicine Physician providers in California
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 433 | $3K | |
| 2019 | 3,921 | $61K | |
| 2020 | 4,355 | $58K | |
| 2021 | 3,557 | $53K | |
| 2022 | 4,566 | $85K | |
| 2023 | 5,772 | $95K | |
| 2024incomplete | 2,394 | $41K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 18% | 835 | 796 | $72K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 13% | 5,899 | 5,238 | $52K |
| 90674 | 12% | 1,403 | 1,391 | $47K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 9.3% | 517 | 488 | $37K |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | 9.3% | 2,297 | 2,109 | $37K |
| G9920 | Screening performed and negative | 7.2% | 1,060 | 1,054 | $28K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 3.2% | 13 | 12 | $13K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 3.2% | 632 | 616 | $13K |
| 90670 | 3.1% | 58 | 57 | $12K | |
| 90658 | 3.0% | 597 | 594 | $12K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.9% | 1,585 | 1,514 | $12K |
| 10061 | 2.7% | 155 | 154 | $11K |
18 more codes
| 99407 | 2.3% | 2,957 | $9K | |
| 90732 | 2.1% | 78 | $8K | |
| 99401 | 1.7% | 936 | $7K | |
| 17111 | 1.5% | 56 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 1.3% | 2,810 | $5K |
| 58300 | 1.2% | 26 | $5K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 518 | $3K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 103 | $3K |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 230 | $3K |
| 99385 | <1% | 26 | $1K | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | <1% | 76 | $629.54 |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 13 | $279.99 |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 12 | $131.45 |
| 97804 | 0% | 1,680 | $0.00 | |
| 1220F | 0% | 134 | $0.00 | |
| 1170F | 0% | 140 | $0.00 | |
| 3008F | 0% | 12 | $0.00 | |
| 1159F | 0% | 140 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.